IL312679A - Compounds for treating mds-associated anemias and other conditions - Google Patents

Compounds for treating mds-associated anemias and other conditions

Info

Publication number
IL312679A
IL312679A IL312679A IL31267924A IL312679A IL 312679 A IL312679 A IL 312679A IL 312679 A IL312679 A IL 312679A IL 31267924 A IL31267924 A IL 31267924A IL 312679 A IL312679 A IL 312679A
Authority
IL
Israel
Prior art keywords
subject
mds
compound
effective amount
therapeutically effective
Prior art date
Application number
IL312679A
Other languages
English (en)
Hebrew (he)
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of IL312679A publication Critical patent/IL312679A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IL312679A 2021-11-16 2022-11-15 Compounds for treating mds-associated anemias and other conditions IL312679A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163280069P 2021-11-16 2021-11-16
US202263357240P 2022-06-30 2022-06-30
PCT/US2022/049969 WO2023091414A1 (en) 2021-11-16 2022-11-15 Compounds for treating mds-associated anemias and other conditions

Publications (1)

Publication Number Publication Date
IL312679A true IL312679A (en) 2024-07-01

Family

ID=84887868

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312679A IL312679A (en) 2021-11-16 2022-11-15 Compounds for treating mds-associated anemias and other conditions

Country Status (11)

Country Link
US (1) US20250108049A1 (cg-RX-API-DMAC7.html)
EP (1) EP4433057A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024543345A (cg-RX-API-DMAC7.html)
KR (1) KR20240107326A (cg-RX-API-DMAC7.html)
AU (1) AU2022390088B2 (cg-RX-API-DMAC7.html)
CA (1) CA3236880A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001431A1 (cg-RX-API-DMAC7.html)
IL (1) IL312679A (cg-RX-API-DMAC7.html)
MX (1) MX2024005852A (cg-RX-API-DMAC7.html)
TW (1) TW202329935A (cg-RX-API-DMAC7.html)
WO (1) WO2023091414A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024238659A1 (en) * 2023-05-15 2024-11-21 Agios Pharmaceuticals, Inc. Crystalline salts or amorphous forms of 2-((1h-pyrazol-3-yl)methyl)-6-((6-aminopyridin-2-yl)methyl)-4-methyl-4,6-dihydro -5h-thiazolo[5',4':4,5]pyrrolo[2,3-d]pyridazin-5-one
WO2026076363A1 (en) 2024-10-04 2026-04-09 Agios Pharmaceuticals, Inc. Compounds for treating mds-associated anemias and other conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120693A1 (es) 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
MX384883B (es) 2015-06-11 2025-03-14 Agios Pharmaceuticals Inc Métodos para usar activadores de piruvato cinasa.
EP3668513B1 (en) 2017-08-15 2021-11-10 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in treating blood disorders
KR102682430B1 (ko) 2017-11-22 2024-07-08 아지오스 파마슈티컬스 아이엔씨. N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의 결정 형태
JP2022533227A (ja) 2019-05-22 2022-07-21 アジオス ファーマシューティカルズ, インコーポレイテッド N-(4-(4-(シクロプロピルメチル)ピペラジン-1-カルボニル)フェニル)キノリン-8-スルホンアミドの結晶性塩形態

Also Published As

Publication number Publication date
AU2022390088B2 (en) 2026-07-02
WO2023091414A1 (en) 2023-05-25
AU2022390088A1 (en) 2024-05-09
KR20240107326A (ko) 2024-07-09
CA3236880A1 (en) 2023-05-25
MX2024005852A (es) 2024-05-28
CL2024001431A1 (es) 2024-10-25
JP2024543345A (ja) 2024-11-21
US20250108049A1 (en) 2025-04-03
EP4433057A1 (en) 2024-09-25
TW202329935A (zh) 2023-08-01

Similar Documents

Publication Publication Date Title
EP1019036B1 (en) Use of d-methionine to reduce the toxicity of ototoxic drugs and noise
US6156755A (en) Use of pyrimidine derivatives for the prevention of cancer, on their own or in combination with other therapeutic measures
EP1702621B1 (en) Metal/Thiol biocides
US4876278A (en) Zinc glycerolate complex and additions for pharmaceutical applications
JP2004502752A5 (cg-RX-API-DMAC7.html)
CA2501322A1 (en) Quinolinyl-pyrrolopyrazoles
FI3982963T3 (fi) Koostumus, johon sisältyy pridopidiini ja sen analogi, huntingtonin taudin ja sen oireitten hoitoa varten
US5334589A (en) Quinolone carboxylic acid--metal ion--acid complexes
US4073922A (en) Treatment of rheumatoid arthritis and related diseases
KR940006580A (ko) 질병을 치료하기 위한 치환된 사이클로헥산 유도체
EP1177791A3 (en) Use of glycogen phosphorylase inhibitors to inhibit tumor growth
JP2001513506A5 (cg-RX-API-DMAC7.html)
JP2001513110A (ja) 腫瘍治療方法
AU2016295357B2 (en) Therapeutic combinations of orally administered paclitaxel and a P-gp inhibitor for the treatment of cancer
JP2005527575A5 (cg-RX-API-DMAC7.html)
Kaojarern et al. Pharmacokinetics of amikacin in hematologic malignancies
JP2024543345A5 (cg-RX-API-DMAC7.html)
WO1992003135A1 (en) Pharmaceutical compositions containing 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridyl) methylsulfinyl] benzimidazole and an anti-helicobacter agent for the treatment of gastrointestinal disorders
Lacey et al. Comparative pharmacokinetics of bismuth from ranitidine bismuth citrate (GR122311X), a novel anti-ulcerant and tripotassium dicitrato bismuthate (TDB)
US5441963A (en) Potentiation of NMDA antagonists
US5776979A (en) Method of use of cardiotonic drugs and inhibitors of nitric oxide synthesis to alleviate pathologic hypotension
ZA200405021B (en) Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes.
MacGowan et al. Sequential antimicrobial therapy: pharmacokinetic and pharmacodynamic considerations in sequential therapy
US7811609B2 (en) Use of metal compounds to treat gastrointestinal infections
US5707653A (en) Ulcer treating composition comprising sufalcrate and antibiotic